Who are Aripiprazole/Escitalopram combination's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aripiprazole-escitalopram-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Aripiprazole/Escitalopram combination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aripiprazole/Escitalopram combination (Aripiprazole/Escitalopram combination) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic and selective serotonin reuptake inhibitor combination. Area: Psychiatry.

marketed Atypical antipsychotic and selective serotonin reuptake inhibitor combination Dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor (partial agonist), serotonin transporter (SERT inhibitor) Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Aripiprazole/Escitalopram combination (Aripiprazole/Escitalopram combination) — Massachusetts General Hospital. This combination uses aripiprazole (a dopamine D2 receptor partial agonist) and escitalopram (a selective serotonin reuptake inhibitor) to modulate both dopaminergic and serotonergic neurotransmission for psychiatric symptom management.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aripiprazole/Escitalopram combination TARGET	Aripiprazole/Escitalopram combination	Massachusetts General Hospital	marketed	Atypical antipsychotic and selective serotonin reuptake inhibitor combination	Dopamine D2 receptor (partial agonist), serotonin 5-HT1A receptor (partial agonist), serotonin transporter (SERT inhibitor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic and selective serotonin reuptake inhibitor combination class)

Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aripiprazole/Escitalopram combination — Competitive Intelligence Brief. https://druglandscape.com/ci/aripiprazole-escitalopram-combination. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab